ASRT vs. VTVT, CMRX, ONCY, GNLX, PRPH, RVPH, ACRS, AFMD, MIST, and IFRX
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include vTv Therapeutics (VTVT), Chimerix (CMRX), Oncolytics Biotech (ONCY), Genelux (GNLX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Aclaris Therapeutics (ACRS), Affimed (AFMD), Milestone Pharmaceuticals (MIST), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.
vTv Therapeutics (NASDAQ:VTVT) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.
vTv Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Assertio has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
In the previous week, Assertio had 12 more articles in the media than vTv Therapeutics. MarketBeat recorded 12 mentions for Assertio and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.48 beat Assertio's score of 0.00 indicating that Assertio is being referred to more favorably in the news media.
vTv Therapeutics received 247 more outperform votes than Assertio when rated by MarketBeat users. However, 59.09% of users gave Assertio an outperform vote while only 57.83% of users gave vTv Therapeutics an outperform vote.
vTv Therapeutics has higher earnings, but lower revenue than Assertio. vTv Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Assertio has a consensus target price of $5.50, indicating a potential upside of 418.92%. Given vTv Therapeutics' higher probable upside, analysts plainly believe Assertio is more favorable than vTv Therapeutics.
17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 1.7% of vTv Therapeutics shares are held by company insiders. Comparatively, 3.2% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
vTv Therapeutics has a net margin of 0.00% compared to vTv Therapeutics' net margin of -218.28%. vTv Therapeutics' return on equity of 6.30% beat Assertio's return on equity.
Summary
Assertio beats vTv Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
